Renal effects of combined anti-hypertensive treatments;Effetti sulla funzione renale dei trattamenti antipertensivi associati

Recenti Progressi in Medicina

Volumn 101, Issue 2, 2010, Pages 70-77

  Gallieni, Maurizio ^a   Olivi, Laura ^a   Mezzina, Nicoletta ^a   Cozzolino, Mario ^a   Cusi, Daniele ^b  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Ace inhibitors; Angiotensin receptor blockers; Chronic renal failure; Hypertension; Proteinuria

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; CLONIDINE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METHYLDOPA; MINOXIDIL; RAMIPRIL; RESERPINE; SPIRONOLACTONE; TACROLIMUS; TELMISARTAN; TRANDOLAPRIL; VERAPAMIL;

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; HUMAN; HYPERTENSION; HYPOVOLEMIA; KIDNEY DISEASE; KIDNEY INJURY; PROTEINURIA; RENAL PROTECTION; REVIEW; SEPSIS;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIURETICS; FUMARATES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; META-ANALYSIS AS TOPIC; NATRIURESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WATER-ELECTROLYTE IMBALANCE;

EID: 77951772337     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: 10.1701/478.5636     Document Type: Review

References (44)

1. Agenzia Italiana del Farmaco, AIFA. Guida all'uso dei farmaci 5. Sulla base del British National Formulary. Elsevier Masson 2008http://www.guidauso- farmaci.it/
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA2003; 289: 2560-2572
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 June; 28(12):1462-1536 Epub 2007 June 11. (Pubitemid 46924065)
4. Frank J. Managing hypertension using combination therapy. Am Fam Physician 2008; 77: 1279-1286
5. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich) 2006; 8: 634-641
6. Giles TD. Rationale for combination therapy as initial treatment for hypertension. J Clin Hypertens (Greenwich) 2003; 5 suppl 3: 4-11.
7. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661
8. Weir MR. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens 2005; 18:100S-105S.
9. Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008; 168: 832-839 (Pubitemid 351620085)
10. Sarafidis PA, Bakris GL. Does evidence support renin-angiotensin system blockade for slowing ne- phropathy progression in elderly persons? Ann Intern Med 2009; 150:731-733
11. 11. Dussol B, Moussi-Frances J, Morange S, SommaDelpero C, Mundler O, Berland Y. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005; 20: 349-353 (Pubitemid 40276891)
12. Kelly RA, Wilcox CS, Mitch WE, Meyer TW, Souney PF, Rayment CM, et al. Response of the kidney to furosemide. II. Effect of Captopril on sodium balance. Kidney Int 1983; 24: 233-239
13. Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther 2005; 19: 301-306 (Pubitemid 41778811)
14. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945
15. The GISEN Group (Gruppo Italiano di Studi Epidemiologia in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
16. Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
17. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140 (Pubitemid 43076710)
18. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936-946 (Pubitemid 40563242)
19. Onuigbo MA. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease. A call for caution. Nephron Clin Pract 2009; 113: c63-c70.
20. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
21. O'Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med 2009; 150: 717-724
22. Hollenberg NK. Is there a pharmacologic basis for combination renin axis blockade? Kidney Int 2005; 68: 2901-2903
23. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094-1103 (Pubitemid 36315589)
24. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-convertingenzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124 (Pubitemid 36092015)
25. Kunz F, Wolbers M, Glass T, Mann JF. The COOPERATE trial: a letter of concern. Lancet 2008; 371: 1575-1576
26. Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28: 273-277 (Pubitemid 40170925)
27. Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-485
28. Kunz R, Friedrich C, Wolbers M, Mann JF. Metaanalysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48. (Pubitemid 351688350)
29. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8-20. (Pubitemid 43912958)
30. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009; 4: 361-368
31. Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G, et al. Protocol of the Longterm Impact of RAS Inhibition on Cardiorenal Outcomes (LÍRICO) randomized trial. J Nephrol 2007; 20: 646-655 (Pubitemid 351266118)
32. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73:1419-1425 (Pubitemid 351770494)
33. Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int 2009; 76: 23-31.
34. Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. New Engl J Med 2008; 358: 2433-2446 (Pubitemid 351793017)
35. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068 (Pubitemid 26293326)
36. Del Vecchio L, Procaccio M, Viganò S, Cusi D. Mechanisms of disease. The role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol 2007; 3: 42-49
37. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Doubleblind, placebo-controlled study of the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1:256-262
38. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
39. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542-551
40. Palmer BF: Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256-1261 (Pubitemid 35176246)
41. Ruggenenti P, Remuzzi G. Proteinuria: Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol. 2009; 5: 436-437
42. Gallieni M, Cozzolino M, Brancaccio D, Giovannini M. Renal outcomes in the ONTARGET study. Lancet 2008; 372: 2019.
43. Gossmann J, Thurmann P, Bachmann T, Weller S, Kachel HG, Schoeppe W, et al. Mechanism of angiotensin Converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50: 973-978 (Pubitemid 26302687)
44. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008; 19: 1213-1224